Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Impedimed Limited ( (AU:IPD) ).
ImpediMed Limited has disclosed a change in the shareholding of director Fiona Bones, who received 100,563 ordinary shares on 14 January 2026, increasing her holding to 1,973,309 shares. The new shares were issued in lieu of 15% of her director fees for the quarter ended 31 December 2025, signalling continued alignment of board compensation with equity ownership, though the company reported no related changes in director interests in contracts or any trading during a closed period.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian-listed medical technology company that develops and commercialises non-invasive bioimpedance spectroscopy devices, primarily used for the early detection and management of conditions such as lymphedema and fluid status monitoring. Its products target healthcare providers and hospital systems, positioning the company within the medical diagnostics and monitoring segment of the healthcare industry.
Average Trading Volume: 1,179,706
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$71.34M
Learn more about IPD stock on TipRanks’ Stock Analysis page.